RNAi
-
【Product for Licensing】siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD)
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
【Product for Licensing】siRNA Therapeutics Targeting INHBE and another target
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Congratulations to Alnylam and patients who may benefit from this exciting progress!
-
乘风破浪 | RNA疗法:从科学到商业的“转录组”
⬆️欢迎参加2020中国新药CMC高峰论坛! 本文转自BCG波士顿咨询,点击阅读原文 RNA技术经历了诸多坎坷起伏后,开始进入蓬勃发展阶段,不但技术种类从RNAi扩充到新兴的m…
-
杨森RNAi疗法最新披露丨功能性治愈乙肝!沉默转录 停药48周持久应答!
⬆️ 欢迎参加2020中国新药CMC高峰论坛! 本文来源:会会药咖(ID:huihuiyaoka) 编译:刘六六 在刚刚结束的第55届欧洲肝脏研究学会(EASL2020)线上会议上…
-
壹周药讯|赛诺菲、吉利德等MNC本周均有大动作
药物篇 信达生物宣布抗TIGIT单克隆抗体I期临床研究完成首例患者给药 近日,信达生物制药宣布,其重组全人源抗含免疫球蛋白基序和免疫受体酪氨酸抑制基序结…